Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

BP slashes green spend, ups fossil fuel investments in major strategy 'reset'

(Sharecast News) - BP is to slash its investments into low-carbon and alternative fuels and raise its spending in oil and gas as part of fundamental "reset" to its strategy, the energy giant revealed on Wednesday, causing shares to drop into the red. The moves are part of a plan to significantly reallocate capital to grow free cash flow, returns and long-term shareholder value, BP said, with structural cost reductions of $4-5bn expected to be made by the end of 2027.

Capital expenditure is expected to total $13-15bn each year until 2027, some $1-3bn lower than the amount spent in 2024.

To achieve this, the company said it is only making "disciplined" and "selective" investments into its so-called transition businesses, which comprise biogas, biofuels, EV charging, hydrogen, carbon capture and storage (CCS) and other renewables. As such, investment in these areas would be just $1.5-2bn per annum, over $5bn a year lower than previous guidance.

Meanwhile, annual capex into oil and gas would be increased to $10bn as it ramps up production capacity to 2.3-2.5mmboed by 2030.

BP is also targeting $20bn of divestments by 2027, including potential proceeds from solar developer Lightsource bp, and said it would conduct a strategic review of the Castrol lubricants division.

Net debt is expected to reduce to $14-18bn by the end of 2027, down from the $23bn position registered at the end of 2024.

"Today we have fundamentally reset bp's strategy," said chief executive Murray Auchincloss.

"We are reducing and reallocating capital expenditure to our highest-returning businesses to drive growth, and relentlessly pursuing performance improvements and cost efficiency. This is all in service of sustainably growing cash flow and returns."

The stock was down 1.5% at 430.20p by 1030 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.